For U.S. Healthcare Professionals Only
+|Aa|-
Resources
Library

InBalance Patient Education Library

Patients can access the InBalance library of resources

Learn more at Renassist.com
or call
1-800-847-0069

Resources

Sanofi Renal is committed to the nephrology community.

  • Sanofi provides dedicated and knowledgeable sales and reimbursement teams to partner with healthcare practitioners, providing care to CKD patients on dialysis.

Dedicated clinical science specialists (CSSs)

A dedicated CSS can provided educational resources for HCPs, including in-service decks and reprint carriers.

Access resources and programs

Renassist® case managers can help identify Renvela® reimbursement solutions for patients with or without prescription coverage.

  • Speak with your regional case manager by calling 1-800-847-0069 or visit Renassist.com to learn more

InBalance patient education

InBalance is a series of patient materials that provide educational information, food guides, and interactive games designed to help patients understand their disease, dialysis, and treatment.

Indication

Renvela® (sevelamer carbonate) is used to control phosphorus levels in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.

Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.

Please see additional Important Safety Information.

Please see Full Prescribing Information for Renvela® or Full Prescribing Information for Renagel®

If you have patients who are having trouble with their Renvela prescription coverage, we may be able to help.
Certain restrictions may apply.

Learn more at Renassist.com.

Indication

Renvela® (sevelamer carbonate) is used to control phosphorus levels in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.

Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

  • Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients.
  • Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
  • Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
  • Uncommon cases of difficulty swallowing the Renagel or Renvela tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela suspension in patients with a history of difficulty swallowing.
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
  • Serum bicarbonate and chloride levels should be monitored.
  • Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
  • Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.

Please see Full Prescribing Information for Renvela® or Full Prescribing Information for Renagel®.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Important Safety Information

Sevelamer is contraindicated in patients with bowel obstruction and in patients with known hypersensitivity to sevelamer carbonate or sevelamer hydrochloride or to any of the excipients. Click here to read more.